1. Home
  2. AYTU vs WVVI Comparison

AYTU vs WVVI Comparison

Compare AYTU & WVVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • WVVI
  • Stock Information
  • Founded
  • AYTU N/A
  • WVVI 1983
  • Country
  • AYTU United States
  • WVVI United States
  • Employees
  • AYTU N/A
  • WVVI N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • WVVI Beverages (Production/Distribution)
  • Sector
  • AYTU Health Care
  • WVVI Consumer Staples
  • Exchange
  • AYTU Nasdaq
  • WVVI Nasdaq
  • Market Cap
  • AYTU 19.7M
  • WVVI 20.4M
  • IPO Year
  • AYTU N/A
  • WVVI N/A
  • Fundamental
  • Price
  • AYTU $2.36
  • WVVI $5.00
  • Analyst Decision
  • AYTU Strong Buy
  • WVVI
  • Analyst Count
  • AYTU 2
  • WVVI 0
  • Target Price
  • AYTU $10.00
  • WVVI N/A
  • AVG Volume (30 Days)
  • AYTU 77.6K
  • WVVI 3.0K
  • Earning Date
  • AYTU 11-12-2025
  • WVVI 11-11-2025
  • Dividend Yield
  • AYTU N/A
  • WVVI N/A
  • EPS Growth
  • AYTU N/A
  • WVVI N/A
  • EPS
  • AYTU N/A
  • WVVI N/A
  • Revenue
  • AYTU $81,659,000.00
  • WVVI $38,384,350.00
  • Revenue This Year
  • AYTU N/A
  • WVVI N/A
  • Revenue Next Year
  • AYTU $2.00
  • WVVI N/A
  • P/E Ratio
  • AYTU $12.93
  • WVVI N/A
  • Revenue Growth
  • AYTU 0.41
  • WVVI N/A
  • 52 Week Low
  • AYTU $0.95
  • WVVI $3.17
  • 52 Week High
  • AYTU $2.85
  • WVVI $7.18
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 55.26
  • WVVI 58.39
  • Support Level
  • AYTU $2.21
  • WVVI $4.80
  • Resistance Level
  • AYTU $2.38
  • WVVI $5.09
  • Average True Range (ATR)
  • AYTU 0.13
  • WVVI 0.18
  • MACD
  • AYTU 0.01
  • WVVI 0.09
  • Stochastic Oscillator
  • AYTU 73.08
  • WVVI 90.85

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About WVVI Willamette Valley Vineyards Inc.

Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.

Share on Social Networks: